Rezolute Inc is trading 6.1% up at $4.59, extending a rally sparked by a significant analyst upgrade and positive clinical outlook.
- Guggenheim raised its price target to $11.00 and designated the stock a Best Idea, citing promising clinical data despite the company's pre-revenue status.
- The upward momentum follows a sharp jump on June 15, suggesting sustained investor confidence in the wake of the bullish analyst commentary.
- Today's gains come even as major indices trade mixed and broader growth stocks face selling pressure.